BIOM3004 Practice Exam Questions

Discuss the role of positive and negative regulators in haematopoiesis.

Several aetiological factors are associated with leukaemogenesis." Discuss this
statement with reference to the relevant cellular and molecular mechanisms.

Correct diagnosis and monitoring of haematological malignancies are fundamental
to treatment. Discuss this statement.

Cytotoxic chemotherapy for haematological malignancies is likely to be replaced
by more innovative treatment strategies in the near future. Discuss this statement.

Describe the steps involved in the absorption and assimilation of iron culminating in
its incorporation into the developing red cell.

Discuss the following statement: The symptomatic severity of an enzymopathy
depends upon the position that the deficient enzyme occupies in the Embden-
Meyerhof pathway.

Review, using named examples, the diversity of congenital abnormalities intrinsic to
red blood cells that may result in their premature loss or destruction.

Describe the infectious agents of relevance to the UK that can be transmitted by
transfusion and the steps the Transfusion Service takes to minimise the risk of their
transmission.

Discuss the clinical significance and molecular biology of two blood group systems,
one that give rise to carbohydrate and one to protein-dependent blood group
antigens.

Discuss the molecular basis, clinical significance and possible functions of one
major and one minor blood group system that are known to cause haemolytic
disease of the foetus and newborn (HDFN).

Discuss, using named examples, where and how therapeutic interventions may be
beneficial in haemostatic disorders.

Haemostasis is an extremely well regulated process in health. Discuss this
statement.

Discuss the causes, consequences and treatment of qualitative and quantitative
defects of platelets.

Describe the pathology and current clinical management of alloimmune diseases of
the foetus and newborn.

Discuss the major immunological events that occur during organ rejection, and how
this can be managed clinically.

Evaluate the relative merits of the alternative sources of haematopoietic stem cells
for the treatment of leukaemia by transplantation.